Laminar Pharma's LAM561, combined with standard chemoradiotherapy, demonstrates significant progression-free survival improvement in MGMT-methylated glioblastoma patients, with PFS extending to 86.4 weeks versus 54.7 weeks in the placebo group.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.